NewLink Genetics Corporation Closes $30 Million Series C Preferred Financing
* Reuters is not responsible for the content in this press release.
AMES, Iowa, Nov. 5 /PRNewswire/ -- NewLink Genetics Corporation announced
today that it has closed a $30 million Series C financing to accelerate the
clinical development of its therapeutic cancer products. Total cash raised in
2009 under a combination of the previously announced Series D Preferred and
the remaining shares in the Series C Preferred totaled just under $20 million.
"NewLink is continuing to accrue patients in Phase 2 studies evaluating drugs
developed out of its HyperAcute cancer immunotherapy platform," said Dr.
Charles Link, Chairman and Chief Executive Officer of NewLink Genetics
Corporation. "The proceeds of this financing will be used both to expand our
cGMP manufacturing capacity and to aggressively move our lead immunotherapy
product for pancreatic cancer into pivotal clinical studies."
About NewLink Genetics Corporation
NewLink Genetics Corporation is a biopharmaceutical company applying
innovative approaches to create new therapeutic agents for patients with
cancer and infectious diseases. Its technologies are designed to enhance the
patient's immune system, enabling the body's immune cells to attack their
intended target.
Contact
NewLink Genetics Corporation
Gordon Link, CFO, 515-296-4351
SOURCE NewLink Genetics Corporation
Gordon Link, CFO of NewLink Genetics Corporation, +1-515-296-4351
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters